At Apollomics, Purpose Drives Action
Pursuing a global vision of healing for all.
Crossing the borders of innovation
Basing clinical trials on sound mechanistic and scientific rationale.
Cancer Patients are fighting for their lives...
we will fight with them
Imagining a world without cancer.
previous arrow
next arrow
Slider

Apollomics is an innovative biopharmaceutical company committed to the discovery and development of oncology combination therapies.

Apollomics-pipeline_v2

Pipeline

Our-Approach

Science

Apollomics_PR

Events

Our Vision

To become a global leader in the development of novel medicines for cancer patients.

Learn More

Recent News

January 7, 2019

Apollomics, Inc. (previously CBT Pharmaceuticals, Inc.) Raises $100 Million in Series B Financing

December 10, 2018

CBT Pharmaceuticals and Strata Oncology Announce Collaboration to Accelerate Development of CBT-101, a c-Met inhibitor, for Patients with Non-Small Cell Lung Cancer and other Solid Tumors
More News